Latest news for Atlas (NYSE:ATCOpH) Stock

Atlas

Atlas Corp is a global asset manager that owns and operates the businesses in which it invests while focusing on deploying capital across multiple verticals to create sustainable value and quality growth opportunities for its shareholders. The company has two business segments: Containership leasing and Mobile power generation. The containership leasing segment owns and operates a fleet of containerships that are chartered pursuant to long-term, fixed-rate charters. The mobile power generation segment owns and operates a fleet of power generation assets, including gas turbines and other equipment, and provides power solutions to customers. Majority of revenue is generated from The Containership Leasing segment.

Atlas Corp

Metsera's common stock is expected to begin trading on the Nasdaq Global Select Market under the ticker symbol "MTSR" on January 31, 2025. The offering is expected to close on February 3, 2025, subject to satisfaction of customary closing conditions.

News

IPOs

MTSR

Reported Earlier, Metsera Prices $275M Initial Public Offering Of 15,277,778 Common Shares At $18/ Share

Macro Economic Events

Econ #s

Economics

France Harmonised Index of Consumer Prices (MoM) Preliminary For January -0.2% Vs. 0.0% Est.; 0.2% Prior

France Consumer Price Index (MoM) Preliminary For January -0.1% Vs. 0.0% Est.; 0.2% Prior

Reported Earlier, Medical Properties Trust Prices $1.5B 8.500% Senior Secured Notes And €1B 7.000% Senior Secured Notes, Both Maturing In 2032

Canada&#8217;s Foreign Minister Melanie Joly warned that proposed U.S. tariffs could force America to rely on Venezuelan oil imports, as tensions escalate ahead of President Donald Trump&#8216;s <a href="https://www.benzinga.com/government/regulations/25/01/43353698/trump-slaps-25-tariffs-on-canada-mexico-loonie-peso-slide-oil-climbs">planned 25% levy on Canadian goods starting Feb. 1</a>.
What Happened: In an interview <a href="https://www.ft.com/content/bb8238b6-11c5-4d0c-a489-04f187ceb88c">with</a> the Financial Times, Joly emphasized Canada&#8217;s strategic importance as an oil supplier, noting that Canadian crude is currently sold at a discount to U.S. refiners in Texas. The warning comes as Trump confirmed sweeping tariffs against both Canada and Mexico, citing concerns over immigration, trade deficits, and drug trafficking.
"There's no other option on the table, and this administration doesn't want to work with Venezuela," Joly said.
The energy trade stakes are significant. Canada supplies approximately 20% of U.S. oil consumption and 60% of imported crude. Many U.S. refineries are specifically configured for the heavy crude grades produced by Canada and Venezuela, rather than the lighter oil from America&#8217;s shale fields.
See Also: <a href="https://www.benzinga.com/25/01/43376717/colgate-palmolive-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">Colgate-Palmolive Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a>
Why It Matters: Markets reacted sharply to Trump&#8217;s announcement, with the Invesco CurrencyShares Canadian Dollar Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXC#NYSE">FXC</a>) falling 0.6% and the USD/CAD rate climbing to 1.4480. The United States Oil Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>) saw initial gains as traders weighed supply chain implications.
Canadian officials are mounting a diplomatic offensive to prevent what could become the first major trade war of Trump&#8217;s potential new administration. Energy Minister Jonathan Wilkinson has threatened retaliatory tariffs on American goods, including steel and orange juice, while Ottawa has pledged $1 billion for border security improvements.
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) declined in late trading Thursday as investors assessed the potential economic impact of escalating trade tensions between the longtime allies.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43376517/chevron-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">Chevron Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>
Image Via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

Trump's Tariffs Could Force US To Buy Venezuelan Oil: 'There's No Other Option On The Table,' Says Canada's Foreign Minister Melanie Joly

Daiichi Sankyo Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DSNKY#OTC">DSNKY</a>) reported quarterly earnings of $0.22 per share. This is a 120 percent increase over earnings of $0.10 per share from the same period last year. The company reported $3.18 billion in sales this quarter. This is a 4.29 percent increase over sales of $3.05 billion the same period last year.

Earnings

DSNKY

Daiichi Sankyo Co Q4 EPS $0.22 Up From $0.10 YoY, Sales $3.18B Up From $3.05B YoY

On Thursday, during Apple Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) <a href="https://in.benzinga.com/news/earnings/25/01/43355688/apple-q1-earnings-revenue-beat-eps-beat-iphone-sales-slip-installed-base-climbs-to-all-time-high-our-best-quarter-ever">first-quarter earnings</a> call, CEO Tim Cook was questioned about the potential impact of President Donald Trump&#8217;s tariff policies on the company.
What Happened: When asked by analyst Atif Malik from Citi about the potential effects of tariffs on Apple&#8217;s products and consumer demand, Cook stated, &#8220;We are monitoring the situation and don&#8217;t have anything more to add than that.&#8221;
The lack of clarity from Cook comes as Apple navigates a complex global market, where tariffs could significantly impact its supply chain and pricing strategies.
See Also:&nbsp;<a href="https://www.benzinga.com/news/legal/25/01/43325503/mark-zuckerbergs-meta-pays-trump-25-million-to-settle-lawsuit-over-facebook-instagram-ban-after-jan-6-riot-a-big-year-for-redefining-our-relationships-with-governments" target="_blank" rel="noreferrer noopener">Mark Zuckerberg&#8217;s Meta Pays Trump $25 Million To Settle Lawsuit Over Facebook, Instagram Ban After Jan. 6 Riot: ‘A Big Year For Redefining Our Relationships With Governments&#8217;</a>
Key Risks From Proposed Tariffs
Semiconductor Tariffs: <a href="https://www.benzinga.com/markets/equities/25/01/43258081/trump-proposes-tariffs-on-taiwans-semiconductor-and-pharmaceutical-imports-amid-tsmcs-65-billion-expansion-plans">Trump's proposed 25% to 100% duties</a> on foreign-made chips could disrupt Apple's supply of custom silicon from Taiwan Semiconductor Manufacturing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>), even as the company ramps up its production facility with $6.6 billion in CHIPS Act funding.
Rising Consumer Prices: A 60% tariff on Chinese imports could drive smartphone prices up by 26%, potentially forcing Apple to add approximately $300 in taxes to a $1,000 iPhone. Chinese suppliers have been Apple&#8217;s largest group of suppliers since 2020, growing from 48 in 2022 to 52 in 2023.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Complications in Nearshoring: While Apple has expanded production to Mexico and India—investing in Indian iPhone manufacturing and tapping Foxconn for <a href="https://www.benzinga.com/news/earnings/25/01/42808796/foxconn-posts-record-revenue-rides-high-on-ai-server-demand-and-nvidia-partnership">AI server production</a> in Mexico —<a href="https://in.benzinga.com/government/regulations/25/01/43353698/trump-slaps-25-tariffs-on-canada-mexico-loonie-peso-slide-oil-climbs">Trump's tariffs</a> on Mexican and Canadian goods could undermine these efforts.
Cook's Playbook For Navigating Tariffs
During the first Trump presidency from 2017 to 2021, Cook was a <a href="https://www.benzinga.com/24/11/42158580/how-tim-cooks-strategy-to-win-over-trump-gave-apple-a-competitive-edge-and-why-sundar-pichai-mark-zuckerberg-and-others-might-be-following-his-playbook">frequent visitor</a> to the White House. However, his interactions with the Joe Biden administration have been minimal.
In 2019, Cook successfully lobbied for Mac Pro tariff exemptions by gifting Trump a $6,000 unit and shifting limited production to Texas.
Earlier this month, it was reported that Cook contributed <a href="https://www.benzinga.com/25/01/42801809/apple-ceo-tim-cook-reportedly-donates-1-million-to-trump-inauguration-joins-ranks-of-mark-zuckerberg-jeff-bezos-and-sam-altman">$1 million to Trump&#8217;s</a> inaugural committee. This came after a Mar-a-Lago dinner meeting and post-election congratulations.
On Thursday, the iPhone maker reported fiscal <a href="https://in.benzinga.com/news/earnings/25/01/43355688/apple-q1-earnings-revenue-beat-eps-beat-iphone-sales-slip-installed-base-climbs-to-all-time-high-our-best-quarter-ever">first-quarter revenue</a> of $124.3 billion, surpassing analyst expectations of $124.13 billion.
Price Action: Apple&#8217;s stock climbed 3.01% in after-hours trading, reaching $244.75. Earlier on Thursday, it closed at $237.59, down 0.74%, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Photo by Laura Hutton on Shutterstock
Check out more of Benzinga&#8217;s Consumer Tech coverage by <a href="https://www.benzinga.com/topic/consumer-tech">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/01/43221770/apples-ipad-turns-15-today-heres-a-throwback-to-when-steve-jobs-explained-called-it-the-third-category-after-phones-and-notebooks" target="_blank" rel="noreferrer noopener">Apple&#8217;s iPad Turns 15 Today: Here&#8217;s A Throwback To When Steve Jobs Explained Called It The ‘Third Category&#8217; After Phones And Notebooks</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

Tech

AAPL

Tim Cook Won't Say How Apple Plans To Handle Trump's Tariff Policies — But Here's What's At Stake For The iPhone Maker

Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) will release its fourth-quarter financial results, before the <a href="https://www.benzinga.com/quote/psx/earnings">opening bell, on Friday, Jan. 31, 2025</a>.
Analysts expect the Houston, Texas-based company to report a quarterly loss at 23 cents per share, versus year-ago earnings of $3.09 per share. Phillips 66 projects quarterly revenue of $32.24 billion, compared to $38.74 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Jan. 6, the company disclosed a definitive deal to acquire EPIC Y-Grade, LP's natural gas liquids (NGL) business for $2.2 billion in cash.
Phillips 66 shares fell 1.1% to close at $120.84 on Thursday.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; .
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/PSX/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Barclays analyst Theresa Chen maintained an Equal-Weight rating and cut the price target from $124 to $115 on Jan. 13, 2025. This analyst has an accuracy rate of 77%.</li>
<li>Wolfe Research analyst Doug Leggate upgraded the stock from Peer Perform to Outperform on Jan. 3, 2025. This analyst has an accuracy rate of 70%.</li>
<li>Wells Fargo analyst Roger Read maintained an Overweight rating and cut the price target from $167 to $161 on Dec. 9, 2024. This analyst has an accuracy rate of 65%.</li>
<li>UBS analyst Spiro Dounis maintained a Buy rating and cut the price target from $150 to $138 on Nov. 4, 2024. This analyst has an accuracy rate of 74%.</li>
<li>Piper Sandler analyst Ryan Todd maintained an Overweight rating and raised the price target from $136 to $144 on Oct. 8, 2024. This analyst has an accuracy rate of 68%.</li>
</ul>
Considering buying PSX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="573" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31022956/image-269-1024x573.png" alt="" class="wp-image-759568" style="width:599px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31022956/image-269-1024x573.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31022956/image-269-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31022956/image-269-768x429.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31022956/image-269.png 1150w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/01/43336168/jim-cramer-likes-this-tech-stock-terrific-business-niche-business">Jim Cramer Likes This Tech Stock: &#8216;Terrific Business, Niche Business&#8217;</a></li>
</ul>

Price Target

Pre-Market Outlook

Analyst Ratings

Trading Ideas

Top Wall Street Forecasters Revamp Phillips 66 Price Expectations Ahead Of Q4 Earnings

Dividend Proposal&nbsp;
The Novartis Board of Directors proposes a dividend payment of CHF 3.50 per share for 2024, up 6.1% from CHF 3.30 per share in the prior year, representing the 28th consecutive dividend increase since the creation of Novartis in December 1996. Shareholders will vote on this proposal at the AGM on March 7, 2025.

Dividends

Novartis Proposes 6.1% Dividend Increase To CHF 3.50 Per Share For 2024, Pending Shareholder Approval At AGM

2025 outlook Barring unforeseen events; growth vs prior year in cc
&nbsp;Net sales are Expected to grow mid- to high-single-digit&nbsp;
Core operating income is Expected to grow high single to low double-digit

Guidance

Novartis Expects 2025 Sales Growth Of Mid- To High-Single Digit, And Core Operating Income Increase Of High Single To Low Double-Digit

Seiko Epson (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SEKEY#OTC">SEKEY</a>) reported quarterly earnings of $0.24 per share. This is a 60 percent increase over earnings of $0.15 per share from the same period last year. The company reported $2.30 billion in sales this quarter. This is a 4.05 percent decrease over sales of $2.39 billion the same period last year.

SEKEY

Seiko Epson Q3 EPS $0.24 Up From $0.15 YoY, Sales $2.30B Down From $2.39B YoY

Novartis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) reported quarterly earnings of $1.98 per share which beat the analyst consensus estimate of $1.81 by 9.39 percent. This is a 29.41 percent increase over earnings of $1.53 per share from the same period last year. The company reported quarterly sales of $13.153 billion which beat the analyst consensus estimate of $12.811 billion by 2.67 percent. This is a 15.14 percent increase over sales of $11.423 billion the same period last year.

Earnings Beats

Novartis Q4 2024 Adj. EPS $1.98 Beats $1.81 Estimate, Sales $13.153B Beat $12.811B Estimate

MESO

Reported Earlier, Mesoblast Provides Ryoncil Commercial Launch Update And Highlights Key Milestones In Late-Stage Pipeline

Colgate-Palmolive Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) will release earnings results for its fourth quarter before the <a href="https://www.benzinga.com/quote/CL/earnings">opening bell on Friday, Jan. 31, 2025.</a>
Analysts expect the New York-based company to report quarterly earnings at 89 cents per share, up from 87 cents per share in the year-ago period. Colgate-Palmolive projects to report revenue of $4.99 billion for the recent quarter, compared to $4.95 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Dec. 11, the company's Board of Directors declared a quarterly cash dividend of 50 cents per common share.
Colgate-Palmolive shares gained 1.5% to close at $90.89 on Thursday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/cl/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Stifel analyst Mark Astrachan maintained a Hold rating and cut the price target from $101 to $95 on Jan. 17, 2025. This analyst has an accuracy rate of 75%.</li>
<li>TD Cowen analyst Robert Moskow maintained a Buy rating and slashed the price target from $110 to $100 on Jan. 8, 2025. This analyst has an accuracy rate of 67%.</li>
<li>Wells Fargo analyst Chris Carey maintained an Underweight rating and lowered the price target from $92 to $83 on Jan. 7, 2025. This analyst has an accuracy rate of 61%.</li>
<li>Deutsche Bank analyst Steve Powers downgraded the stock from Buy to Hold but boosted the price target from $107 to $109 on Sept. 9, 2024. This analyst has an accuracy rate of 67%.</li>
<li>Morgan Stanley analyst Dara Mohsenian maintained an Overweight rating and increased the price target from $103 to $111 on July 29, 2024. This analyst has an accuracy rate of 70%.</li>
</ul>
Considering buying CL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="439" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31021008/image-268-1024x439.png" alt="" class="wp-image-759537" style="width:604px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31021008/image-268-1024x439.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31021008/image-268-300x129.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31021008/image-268-768x329.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31021008/image-268.png 1115w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/01/43336168/jim-cramer-likes-this-tech-stock-terrific-business-niche-business">Jim Cramer Likes This Tech Stock: &#8216;Terrific Business, Niche Business&#8217;</a></li>
</ul>

Colgate-Palmolive Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

The Company was originally notified by NYSE American of non-compliance with the continued listing standards as a result of rescheduling our 2024 Annual Meeting in 2025. With the meeting now complete, Belpointe OZ has fulfilled its obligations, and we have been formally notified that we have regained compliance with all applicable listing requirements.

Reported Earlier, Belpointe OZ Regains NYSE American Compliance Following Successful 2024 Annual Meeting

The shares are expected to begin trading on the Nasdaq Global Market on January 31, 2025, under the symbol "MAZE." The offering is expected to close on February 3, 2025, subject to the satisfaction of customary closing conditions.

MAZE

Reported Earlier, Maze Therapeutics Prices $140M Upsized Initial Public Offering Of 8.75M Common Shares At $16/Share

- Agreement means eligible sickle cell disease (SCD) patients in England now have access to CASGEVY -
- Agreement for CASGEVY in transfusion-dependent beta thalassemia (TDT) was previously reached in August 2024 -

Comments

Atlas

News

Latest news for Atlas (NYSE:ATCOpH) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga